Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Inclusion Criteria:

• Male or female outpatients between 18 and 70 years old inclusive;
• symptoms of social anxiety disorders (generalized type) present for at least 1 year prior to Selection Visit;
• had a score of >=60 on the LSAS at the Selection Visit and at the Randomization Visit. Additionally, the clinician's gloal impression of change score must have been >= 2 at the Randomization Visit;
• had a telephone where they could be directly contacted.

Exclusion Criteria:

• History of autism or Asperger's Disease;
• had another primary axis I disorder or fulfilled diagnostic and statistical manual of mental disorders-4th edition (DSM-IV) criteria in the 6 months prior to Screening;
• major depression as measured by a Hamilton Depression Rating Scale (HAM-D-17 items) total score of > 17 and/or a suicide subscale score on the HAM-D-17 items of > 2 at the Selection or Randomization Visit;
• history of electroconvulsive therapy within the prior 3 months;
• history of psychotherapy which was not stable and ongoing for at least 6 months prior to Visit 1;
• clinical history of significantly impaired renal function with an estimated creatinine clearance below 80 mL/min;
• clinically significant medical condition;
• history of any clinically significant allergic condition or allergy to LEV or pyrrolidone derivatives;
• neutrophil count of less than 1800/µL.